Anivive Completes LAVERDIA-CA1 Pivotal Study For Canine Lymphoma
14 Feb 2025 //
PR NEWSWIRE
Anivive Licenses Novel Canine Cancer Therapeutic to Expand Sales & Pipeline
12 Jan 2022 //
PRNEWSWIRE
Anivive Expands Specialty Sales Team
29 Jun 2021 //
PR NEWSWIRE